Israel’s Nectin Therapeutics (see here previously) has started human trials of its NTX1088 cancer treatment. NTX1088 blocks the protein PVR expressed by tumors to suppress the immune system. The treatment also restores DNAM-1, needed to activate anti-cancer T & NK cells.
https://nocamels.com/2022/12/treatment-for-resistant-cancer-patients-raises-25m/